Scientists warn popular vitamin D supplement may have a “previously unknown” downside

Researchers have discovered that vitamin D2 supplements, widely used in fortified foods and medications, may actively reduce the body's levels of vitamin D3, the more potent form of the vitamin. The finding challenges decades of supplementation practices and suggests public health guidelines may need revision.

The study reveals vitamin D3 operates more efficiently than D2 at raising overall vitamin D status in the body. Beyond this metabolic advantage, D3 appears to play a distinct role in immune function that D2 cannot replicate, helping the body combat viral and bacterial infections. This dual benefit underscores a fundamental difference between the two forms that scientists had not fully appreciated.

Vitamin D2, derived from plants and fungi, has long dominated supplement formulations because it is cheaper to produce and remains stable in fortified foods. Vitamin D3, sourced from animal products or synthesized from cholesterol, costs more but converts more readily into the active form the body uses. The research suggests that using D2 may actually undermine D3 levels, creating a net loss in protection.

The implications reach across public health systems globally. Many countries mandate D2 fortification in milk, bread, and cereals. Pharmaceutical companies routinely include D2 in multivitamins and prescription supplements. This study proposes those policies inadvertently compromise immune defense and vitamin D status simultaneously.

Scientists now advocate for prioritizing D3 in supplementation strategies, particularly for vulnerable populations including the elderly, children, and people with limited sun exposure. The shift would increase costs but potentially deliver stronger protection against respiratory infections and other pathogens.

The research prompts careful examination of why D2 retained dominance despite evidence suggesting D3's superiority. Economic incentives in the supplement industry may have slowed recognition of the functional distinction. Public health agencies face pressure to weigh cost considerations against health outcomes when revising recommendations.